Search
Cytotoxic T cell_main
Immune Cell

Cytotoxic T cell

6003€+
Immune Cell

Cytotoxic T cell

  • Tumor-Infiltrating Lymphocytes (TILs) are predominantly found in the microenvironment of tumors, including various types of lymphocytes that have infiltrated in and around tumor tissues.
  • Among them, CD8+ cytotoxic T cells and CD4+ helper T cells are major components.
  • Our approach involves isolating and expanding TILs from a patient’s tumor tissue, then evaluating the efficacy of anticancer agents in a tumor microenvironment containing cancer organoids and TILs.

Price
Organism
Human
Product Type
Organoid + Cytotoxic T cell
Tissue
Adaptive
Disease

Applications

Cancer Organoid

Colorectal Cancer

Non-Small Cell Lung Cancer

Pancreatic Cancer

Breast Cancer

Cholangiocarcinoma

Gastric Cancer

Ovarian Cancer

Professor Lee Chang-seok Eulji University
Customer insight

Advancing K-Beauty with Skin Organoids: A Next-Generation Platform for Non-Animal Testing and High-Precision Cosmetic Innovation

With the global rise of K-beauty, the cosmetics industry continues to grow steadily. Since the ban on animal testing for cosmetics in Korea in 2017, various alternative testing methods have...

Tomocube (Spatial)
Customer insight

HT-X1: A Label-Free Imaging Breakthrough for Organoid-Based Disease Modeling and Drug Screening

Traditional microscopy methods often require fluorescent labeling to analyze cellular structures, which can be time-consuming and invasive. In contrast, our HT-X1 system allows for high-resolution visualization of cellular morphology without...

Seoul National University College of Medicine
Customer insight

Pioneering Spatial Protein Analysis in Korea: Advancing Clinical Pathology with Lambda Biologics’ Support

Traditional protein analysis has primarily focused on quantifying expression levels within tissue samples. However, recent advances in spatial analysis techniques have shifted attention toward evaluating not only expression levels, but...

K Research Institute
Customer insight

ODISEI-Gut Platform Reveals Immune-Boosting Potential of Kimchi-Derived Bacterial Strain

Among the many fermented foods we consume, kimchi is particularly known for containing a diverse range of lactic acid bacteria, which are believed to influence the activation of immune cells...

Bundang Jesaeng General Hospital
Customer insight

Multiplex Marker Analysis Enhances Research Efficiency with 31-Marker Detection on a Single Slide

We conducted a study focused on identifying disease-related markers using patient-derived tissue samples. However, traditional methods limited our ability to analyze multiple candidate markers simultaneously, and the limited availability of...

Description

Table of Contents

Characteristics

Evaluation of the efficacy of an immunotherapeutic agent targeting cytotoxic T cells is possible by co-culturing specific organoids with Primed Cytotoxic T cells, allowing for the selective elimination of particular organoids.
This provides a solution for assessing the effectiveness of immunotherapeutic agents targeting cytotoxic T cells in co-culture with cancer organoids.
Play Video

Principle

Drug Efficacy Evaluation in Co-culture of Tumor Organoids and Cytotoxic T Cell

PD L1 binds to PD 1 and inhibits T cell kiling of tumor cell

Blocking PD L1 or PD 1 allows T cell kiling of tumor cell

When evaluating the efficacy of atezolizumab in co-culture conditions with tumor organoids and tumor-infiltrating lymphocytes or tumor organoids and T cells derived from PBMCs, higher tumor organoid killing was observed in conditions without co-culture with tumor-infiltrating lymphocytes or T cells.
The method of evaluating efficacy by treating a specific mixture of tumor organoids and tumor-infiltrating lymphocytes with anticancer drugs is still at the research level globally, and our company uniquely holds patents and commercialization services related to this. Make your research shine brighter through the only service of its kind in the world.

Read out

Organoid-Based Immunotherapy Evaluation for Anticancer drugs

High Responder to control

Low Responder to control

Our cutting-edge platform brings approach in drug development, empowering clinicians and researchers to transcend beyond the binary classification of responders versus non-responders.
It facilitates a deeper examination of patient-specific responses to approved control drugs at various concentrations.
This technology illuminates the intricate interplay between genetic, regional, and environmental factors and their impact on drug efficacy, providing a path to address the pressing unmet needs in before clinical trail.

This example showcases the potential utility of our platform in identifying optimal partners for combination therapy with Immune Checkpoint Inhibitors (ICIs).
His suggests that Combination B could be a more effective strategy in enhancing the efficacy of ICIs.
This platform is designed to facilitate such discoveries, offering a clear pathway to improve clinical outcomes through strategic drug pairing.

Connect with Us